---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-022633"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-05-22T21:15:41+00:00"
generated_at: "2026-05-22T21:23:01.054931+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anteris Technologies enters $250M ATM equity offering with TD Cowen to fund DurAVR heart valve development

## Summary
- Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.
- Commission payable to TD Cowen is 3.0% of gross proceeds for sales as agent.
- Net proceeds primarily for ongoing development of DurAVR Transcatheter Heart Valve System and working capital.
- Sales may be made on Nasdaq, in negotiated transactions, or block trades; company controls timing and size.
- Offering terminates upon sale of all shares or either party giving 10 days' notice; shelf effective since Jan 8, 2026.

## SEC filing metadata
- accession: 0001140361-26-022633
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-05-22T21:15:41+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126022633/0001140361-26-022633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126022633/ny20074564x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-022633
- JSON: https://secwatch.observer/filing/0001140361-26-022633.json
- Plain text: https://secwatch.observer/filing/0001140361-26-022633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.